| Keywords: |
cancer chemotherapy; cancer survival; treatment outcome; promoter region; gene deletion; cancer combination chemotherapy; temozolomide; glioma; brain neoplasms; antineoplastic agent; genetic predisposition to disease; radiotherapy; editorial; rna interference; vincristine; drug resistance, neoplasm; enzyme activity; chemosensitivity; dna methylation; lomustine; procarbazine; outcome assessment (health care); gene expression regulation, neoplastic; dna; drug mechanism; randomized controlled trials; tumor suppressor proteins; dna repair enzymes; consensus development; world health organization; oligodendroglioma; heterozygosity loss; methylated dna protein cysteine methyltransferase; tumor growth; drug therapy; chromosome deletion; dna modification methylases; drug sensitivity; anaplastic carcinoma; chromosome 1p; antineoplastic protocols; chromosome 19q
|
